TP53 and cyclic hematopoiesis: This may be explained by the exclusion of ATM and most non-TP53 DDR genes from hematologic malignancy panels traditionally used to evaluate CH in the clinic, genetic heterogeneity of TBD patients included across different studies, and patient age differences across studies.